Ambeed.cn

首页 / / / / Pelitinib/培利替尼

Pelitinib/培利替尼 {[allProObj[0].p_purity_real_show]}

货号:A111899 同义名: EKB-569; WAY-EKB 569

Pelitinib是一种不可逆的EGFR抑制剂,IC50为38.5 nM。

Pelitinib/培利替尼 化学结构 CAS号:257933-82-7
Pelitinib/培利替尼 化学结构
CAS号:257933-82-7
Pelitinib/培利替尼 3D分子结构
CAS号:257933-82-7
Pelitinib/培利替尼 化学结构 CAS号:257933-82-7
Pelitinib/培利替尼 3D分子结构 CAS号:257933-82-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Pelitinib/培利替尼 纯度/质量文件 产品仅供科研

货号:A111899 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 EGFR/ErbB1 ErbB3 ErbB4 HER2/ErbB2 mutant EGFR 其他靶点 纯度
WZ-3146 ++++

EGFR (E746_A750/T790M), IC50: 14 nM

EGFR (E746_A750), IC50: 2 nM

99%+
Daphnetin +

EGFR, IC50: 7.67 μM

PKA,PKC 95%
Lifirafenib ++

EGFR, IC50: 29 nM

+

EGFR(T790M/L858R), IC50: 495 nM

98%
PD168393 ++++

EGFR, IC50: 0.70 nM

99%+
Nazartinib ++

mutant EGFR, Ki: 0.031 μM

++

mutant EGFR, Ki: 0.031 μM

98%
Norcantharidin 98%
CL-387785 ++++

EGFR, IC50: 370 pM

98%
WHI-P154 +++

EGFR, IC50: 4 nM

Src,VEGFR 98%
Tyrphostin A9 +

EGFR, IC50: 460 μM

PDGFR 98%
AG 555 +

EGFR, IC50: 0.7 μM

98%
AG 494 +

EGFR, IC50: 1.2 μM

99%+
AG-556 +

EGFR, IC50: 5 μM

98%
RG13022 +

EGFR, IC50: 4 μM

99%+
Tyrphostin RG 14620 99%+
Vandetanib +

EGFR, IC50: 500 nM

99%
CNX-2006 ++

mutant EGFR, IC50: <20 nM

++

mutant EGFR, IC50: <20 nM

99%
AZD3759 ++++

EGFR (WT), IC50: 0.3 nM

EGFR (L858R), IC50: 0.2 nM

98%
Erlotinib ++++

EGFR, IC50: 2 nM

95%
Saracatinib +++

EGFR, IC50: 5 nM

EGFR (L861Q), IC50: 4 nM

99%+
AG1557 99%
Rociletinib ++

EGFR (wt), Ki: 303.3 nM

EGFR (L858R/T790M), Ki: 21.5 nM

98%
AG490 +

EGFR, IC50: 0.1 μM

98%
Cetuximab ++++

EGFR, Kd: 0.39 nM

95%
Osimertinib ++

L858R/T790M EGFR, IC50: 11.44 nM

WT EGFR, IC50: 12.92 nM

98%
Osimertinib mesylate 98% (Content MsOH 15.2-18.2%)
Chrysophanol mTOR 98%
PD153035 ++++

EGFR, Ki: 5.2 pM

99%+
Olmutinib BTK 99%+
WZ4002 ++++

EGFR (L858R), IC50: 2 nM

EGFR (L858R/T790M), IC50: 8 nM

99%+
Icotinib +++

EGFR, IC50: 5 nM

99%
Desmethyl Erlotinib HCl ++++

EGFR, IC50: 2 nM

98%
Cyasterone 99%+
PP 3 +

EGFR tyrosine kinase, IC50: 2.7 μM

98%
WZ8040 99%+
(-)-Epigallocatechin Gallate 99%
AG 18 +

EGFR, IC50: 35 μM

99%+
O-Desmethyl gefitinib ++

EGFR, IC50: 36 nM

99%
Falnidamol 99%+
AZ-5104 ++++

EGFR (L858R), IC50: 6 nM

EGFR (L861Q) , IC50: <1 nM

+++

ErbB4, IC50: 7 nM

BRK 99%+
Butein 95%
Genistein 98%
SU5214 +

EGFR, IC50: 36.7 μM

99%+
Naquotinib 99%+
Gefitinib ++

EGFR, IC50: 15.5 nM

+

EGFR (858R/T790M), IC50: 823.3 nM

98%
Theliatinib +++

WT EGFR, IC50: 3 nM

++

EGFR T790M/L858R, IC50: 22 nM

99%
Lazertinib ++++

L858R/T790M EGFR, IC50: 2 nM

WT EGFR, IC50: 76 nM

++++

Del19/T790M, IC50: 1.7 nM

99%+
Gefitinib-based PROTAC 3 ++

EGFR, DC50: 22.3 nM

99%+
MTX-211 PI3K 98%
(E)-AG 99 99%+
Licochalcone D Caspase,PARP 99%
Zipalertinib +++

EGFR WT, IC50: 8 nM

EGFR (L861Q), IC50: 4.1 nM

+++

HER4, IC50: 4 nM

++++

EGFR L858R, IC50: 2 nM

EGFR(d746-750), IC50: 1.4 nM

97%
JND3229 +++

EGFR WT, IC50: 6.8 nM

++

EGFR L858R/T790M, IC50: 30.5 nM

99%+
Firmonertinib mesylate 99%+
Tyrphostin AG30 99%+
EGFR-IN-12 ++

EGFR, IC50: 21 nM

99%+
Mobocertinib 98%
(Rac)-JBJ-04-125-02 95%
(S)-Sunvozertinib 99%
BLU-945 95%
Poziotinib +++

HER1, IC50: 3.2 nM

++

HER4, IC50: 23.5 nM

+++

HER2, IC50: 5.3 nM

98%
TAK-285 ++

EGFR/HER1, IC50: 23 nM

+

HER4, IC50: 260 nM

++

HER2, IC50: 17 nM

99%+
ARRY-380 analog 99%
Canertinib ++++

EGFR, IC50: 1.5 nM

+++

ErbB2, IC50: 9.0 nM

99%+
Dacomitinib +++

EGFR, IC50: 6.0 nM

+

ErbB4, IC50: 73.7 nM

+

ErbB2, IC50: 45.7 nM

98%
EGFR/ErbB-2/ErbB-4 inhibitor-2 +

ErbB4, IC50: 1.91 μM

+

ErbB2, IC50: 0.08 μM

99%+
(E/Z)-CP-724714 ++

HER2/ErbB2, IC50: 10 nM

95%
Lapatinib ++

EGFR, IC50: 10.8 nM

+

ErbB4, IC50: 367 nM

+++

ErbB2, IC50: 9.2 nM

98%
AEE788 ++++

EGFR, IC50: 2 nM

+

HER4/ErbB4, IC50: 160 nM

+++

HER2/ErbB2, IC50: 6 nM

c-Fms/CSF1R 98+%
AV-412 free base ++++

EGFR, IC50: 0.75 nM

++

ErbB2, IC50: 19 nM

++++

EGFRT790M, IC50: 0.79 nM

EGFRL858R/T790M, IC50: 0.51 nM

98+%
Neratinib +

EGFR, IC50: 92 nM

+

HER2, IC50: 59 nM

Src 98%
BMS-599626 ++

HER1, IC50: 20 nM

+

HER4, IC50: 190 nM

++

HER2, IC50: 30 nM

98%
Tucatinib +++

ErbB2, IC50: 8 nM

98%
Allitinib ++++

EGFR, IC50: 0.5 nM

++++

ErbB4, IC50: 0.8 nM

+++

ErbB2, IC50: 3.0 nM

99%
Pelitinib +

EGFR, IC50: 38.5 nM

+

ErbB2, IC50: 1.255 μM

Src,Raf 99%+
Sapitinib +++

EGFR, IC50: 4 nM

+++

ErbB3, IC50: 4 nM

+++

ErbB2, IC50: 3 nM

99%+
CUDC-101 +++

EGFR, IC50: 2.4 nM

++

HER2, IC50: 15.7 nM

HDAC 99%+
Varlitinib +++

ErbB1, IC50: 7 nM

++++

ErbB2, IC50: 2 nM

99%+
Afatinib dimaleate ++++

EGFR (wt), IC50: 0.5 nM

EGFR (L858R/T790M), IC50: 0.4 nM

++

HER2, IC50: 14 nM

98%
Canertinib 2HCl +++

EGFR, IC50: 7.4 nM

+++

ErbB2, IC50: 9 nM

99%
Allitinib tosylate ++++

EGFR, IC50: 0.5 nM

EGFR (T790M/L858R), IC50: 12 nM

++++

ErbB4, IC50: 0.8 nM

+++

ErbB2, IC50: 3.0 nM

99%
Tyrphostin AG 528 +

EGFR, IC50: 4.9 μM

+

HER2, IC50: 2.1 μM

97%
Afatinib ++++

EGFR (wt), IC50: 0.5 nM

EGFR (L858R), IC50: 10 nM

++++

ErbB4, IC50: 1 nM

++

HER2, IC50: 14 nM

99%
Pyrotinib dimaleate ++

EGFR, IC50: 0.013 μM

++

HER2, IC50: 0.038 μM

98%
Epertinib HCl ++++

EGFR, IC50: 1.48 nM

+++

HER4, IC50: 2.49 nM

+++

HER2, IC50: 7.15 nM

99%
Tuxobertinib ++++

EGFR, Kd: 0.2 nM

++++

HER2, Kd: 0.76 nM

99%
ALK-IN-1 ++

EGFR(del19), IC50: 36.8 nM

EGFR(C797S/del19), IC50: 138.6 nM

ALK 99%
Brigatinib +

EGFR(C797S/T790M/del19), IC50: 67.2 nM

EGFR(del19), IC50: 39.9 nM

FLT3,ALK 98%
Avitinib ++++

EGFR L858R/T790M, IC50: 0.18 nM

BTK 99%+
EAI045 97%
Almonertinib 99%
BI-4020 ++++

EGFRdel19 T790M C797S, IC50: 0.2 nM

99%+
EGFR-IN-7 ++++

EGFRL858R/T790M, IC50: 0.19 nM

EGFRd746-750/T790M/C797S, IC50: 0.26 nM

99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Pelitinib/培利替尼 生物活性

靶点
  • EGFR/ErbB1

    EGFR, IC50:38.5 nM

  • HER2/ErbB2

    ErbB2, IC50:1.255 μM

描述 EGFR is a member of epidermal growth factor receptor (HER) family. It is a tyrosine kinase that participates in the regulation of cellular homeostasis. EGFR gene mutations and protein overexpression can both activate pathways (Protein Tyrosine Kinase/RTK). Pelitinib (EKB-569) is an irreversible EGFR inhibitor by inhibiting phosphorylation. It can also slightly inhibit SRC, MEK / ERK and erbB2. The inhibitory effect of Pelitinib on EGFR was higher than that of Src, MEK/ERK, Cdk4, c-Met, Raf and ErbB2. The IC50 for EGFR is 32-fold lower than the IC50 for ErbB2. The IC50s of Pelitinib in inhibiting NHEK, A431, MDA-468 cells proliferation were 61, 125 and 260 nM, respectively [3]. The result of in-cell western assay showed that Pelitinib inhibited endogenous total cellular tyrosine and endogenous ERK1/2 phosphorylation in a dose-dependent manner in A431 cells. Pelitinib at 1000 nM can inhibit EGFR and ERK phosphorylation significantly after 60 min incubation [4]. In vitro studies determined that Pelitinib at 100nM and 1,000nM inhibited circa 70% SS1-induced pERK1/2 relative to untreated SS1-stimulated in A431 cells. In vivo , studies showed that Pelitinib treatment resulted in a significant reduction (p < 0.05) in glandular herniations which were present in two of eight (25%) of H. pylori-infected Pelitinib treated gerbils [5].
作用机制 Pelitinib is an irreversible EGFR inhibitor by inhibiting phosphorylation.

Pelitinib/培利替尼 细胞实验

Cell Line
Concentration Treated Time Description References
HEK293 1, 2, 5 μM 3 h To study the inhibition kinetics of pelitinib on ABCB1- and ABCG2-mediated topotecan efflux. Results showed that pelitinib is a competitive inhibitor of both ABCB1 and ABCG2. Br J Pharmacol. 2015 Aug;172(16):4089-106.
A549 3 μM 48 h To evaluate the effect of pelitinib in combination with topotecan on apoptosis in A549 cells after hyperthermia exposure. Results showed that pelitinib significantly enhanced the apoptotic effect of topotecan after hyperthermia. Br J Pharmacol. 2015 Aug;172(16):4089-106.
mouse tracheal epithelial cells 50 µM 7 days To study the effect of PI3K inhibitor on the survival of ciliated epithelial cells, results showed that PI3K inhibitor induced apoptosis of ciliated cells. J Clin Invest. 2006 Feb;116(2):309-21.
mouse tracheal epithelial cells 0.3 µM 7 days To study the effect of EKB-569 on the survival of ciliated epithelial cells, results showed that EKB-569 induced apoptosis of ciliated cells. J Clin Invest. 2006 Feb;116(2):309-21.
SNU449 cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration of SNU449 cells. The results showed that EKB-569 significantly inhibited wound healing of SNU449 cells. BMC Cancer. 2023 Jul 27;23(1):703.
Hep3B cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration of Hep3B cells. The results showed that EKB-569 significantly inhibited wound healing of Hep3B cells. BMC Cancer. 2023 Jul 27;23(1):703.
Huh7 cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration and invasion of Huh7 cells. The results showed that EKB-569 significantly inhibited wound healing and invasion of Huh7 cells, and reduced the activities of MMP-2 and MMP-9. BMC Cancer. 2023 Jul 27;23(1):703.

Pelitinib/培利替尼 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Virus-induced airway epithelial remodeling model Orally 20 mg/kg Once daily for 11 days To study the effect of EKB-569 on virus-induced epithelial remodeling, results showed that EKB-569 prevented increases in ciliated and goblet cells. J Clin Invest. 2006 Feb;116(2):309-21.
BALB/c mice 4T1 tumor model Oral 5 mg/kg, 10 mg/kg, 20 mg/kg Once daily for 14 days To evaluate the anti-tumor effects of pelitinib in the 4T1 tumor model, results showed that pelitinib significantly inhibited tumor volume and weight, and suppressed M2 macrophage polarization and the EMT process J Pharm Anal. 2024 Aug;14(8):100975
C57BL/6J mice Wild-type mice Oral 150 mg/kg of food Daily for 90 days To evaluate the effects of EKB-569 on cardiac function and pathology. Results showed that EKB-569 caused loss, thinning of the left ventricular wall, changes in cardiac function, and increased cardiac fibrosis and apoptotic cell numbers. Toxicol Appl Pharmacol. 2008 May 1;228(3):315-25

Pelitinib/培利替尼 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00072748 Colorectal Neoplasms ... 展开 >> Colonic Neoplasms Rectal Neoplasms 收起 << Phase 2 Completed - -
NCT00098501 Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 << Phase 1 Completed - United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00067548 Non-Small-Cell Lung Carcinoma ... 展开 >> Carcinoma, Non-Small Cell Lung Lung Neoplasms 收起 << Phase 2 Completed - -

Pelitinib/培利替尼 参考文献

[1]Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther. 2004 Jan;3(1):21-7.

[2]Torrance CJ, Jackson PE, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000 Sep;6(9):1024-8.

[3] Torrance CJ, Jackson PE, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000 Sep; 6(9):1024-8

[4] Du Y, Danjo K, et al. In-Cell Western analysis of Helicobacter pylori-induced phosphorylation of extracellular-signal related kinase via the transactivation of the epidermal growth factor receptor. Microbes Infect. 2007 Jun; 9(7):838-46

[5] Crabtree JE, Jeremy AH, et al. Effects of EGFR Inhibitor on Helicobacter pylori Induced Gastric Epithelial Pathology in Vivo. Pathogens. 2013 Oct 14; 2(4):571-90

Pelitinib/培利替尼 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.69mL

2.14mL

1.07mL

21.37mL

4.27mL

2.14mL

Pelitinib/培利替尼 技术信息

CAS号257933-82-7
分子式C24H23ClFN5O2
分子量 467.92
SMILES Code O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(F)C(Cl)=C3)C2=C1)/C=C/CN(C)C
MDL No. MFCD09837868
别名 EKB-569; WAY-EKB 569; WAY-172569
运输蓝冰
InChI Key WVUNYSQLFKLYNI-AATRIKPKSA-N
Pubchem ID 6445562
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

DMSO: 25 mg/mL(53.43 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。